Adenylosuccinate Synthetase Detection

Comprehensive Adenylosuccinate Synthetase Detection, Activity Profiling, and Molecular Characterisation Services

Adenylosuccinate synthetase (ADSS; EC 6.3.4.4) is a critical enzyme in the de novo purine nucleotide biosynthesis pathway, catalysing the conversion of inosine monophosphate (IMP) to adenylosuccinate using aspartate and GTP as substrates. This reaction is the first committed step in the synthesis of AMP from IMP and plays a pivotal role in regulating cellular purine nucleotide pools, energy homeostasis, and cell proliferation. ADSS has two isoforms in humans—ADSS1 (predominantly expressed in muscle) and ADSS2 (ubiquitously expressed)—and its dysregulation has been implicated in muscle disorders, cancer metabolism, and certain inherited metabolic diseases. The accurate and comprehensive detection of ADSS—encompassing enzymatic activity, kinetic parameters, substrate specificity, protein abundance, isoform discrimination, and inhibitor sensitivity—is essential for understanding purine metabolism, diagnosing ADSS deficiency, developing anti‑cancer and anti‑parasitic therapeutics, and ensuring the quality of biological reagents. Our specialised detection platform offers a fully validated suite of biochemical, spectrophotometric, mass spectrometric, and cell‑based assays tailored to ADSS from human, mammalian, microbial, and recombinant sources, delivering the high‑precision, regulatory‑ready data that clients require for research, diagnostics, drug development, and quality assurance.

Scientific, Clinical, and Biotechnological Rationale for ADSS Analysis

Clients seeking ADSS detection services are motivated by a range of strategic objectives. In purine metabolism and cancer research, the primary need is to quantify ADSS activity and protein levels in tumour tissues, cell lines, and biofluids to assess the dependence of cancer cells on de novo purine synthesis and to evaluate the effects of metabolic interventions. In muscle physiology and neuromuscular disorders, ADSS1 deficiency leads to myopathy and exercise intolerance; accurate measurement of ADSS activity and isoform expression is essential for diagnosis and for understanding disease mechanisms. In drug discovery and pharmacology, evaluating the inhibitory potency of novel compounds against ADSS is critical for identifying selective inhibitors with potential as anti‑cancer, anti‑parasitic (e.g., against malaria and leishmaniasis), or immunosuppressive agents. In genetic and metabolic diagnostics, measuring ADSS activity in cultured fibroblasts, lymphocytes, or muscle biopsies supports the diagnosis of adenylosuccinate synthetase deficiency and other purine metabolism disorders. In quality control of enzyme preparations, verifying the activity, purity, and stability of recombinant ADSS standards is essential for assay development and diagnostic kit production. In regulatory submissions, comprehensive data on enzyme activity, selectivity, and stability are required for the approval of novel therapeutics and diagnostic tools. Our service is architected to address these diverse needs with a flexible, ISO 17025‑accredited analytical framework that adapts to the specific ADSS isoform, sample matrix (tissue homogenates, cell lysates, purified recombinant proteins), and client's clinical, research, or regulatory context.

Integrated Analytical Platform for Holistic ADSS Characterisation

Our analytical platform comprises four interconnected modules that collectively deliver a comprehensive evaluation of ADSS quality, activity, and specificity. The Activity Quantification Module employs a validated continuous spectrophotometric assay coupled to pyruvate kinase and lactate dehydrogenase to monitor the production of GDP (or the consumption of GTP) at 340 nm, using IMP and aspartate as substrates. For higher sensitivity and for samples with interfering absorbance, we use a radiometric assay with ¹⁴C‑aspartate or a LC‑MS/MS assay that directly quantifies the formation of adenylosuccinate. We determine the specific activity (U/mg protein) with precision within ±2% RSD and a limit of detection (LOD) as low as 0.001 U/mL. For detailed kinetic characterisation, we calculate Michaelis‑Menten parameters (K_m for IMP, aspartate, and GTP; V_max; k_cat) and inhibition constants (IC₅₀, K_i) for a panel of known inhibitors (e.g., hadacidin, alanosine, and nucleotide analogues) and test compounds, with 95% confidence intervals typically within ±5%. The Isoform‑Specific Quantitation Module uses ELISA with isoform‑specific monoclonal antibodies (anti‑ADSS1, anti‑ADSS2) to quantify protein abundance, providing LOQs of 0.05 ng/mg of total protein and inter‑assay precision < 5%. For absolute quantitation and isoform discrimination, we use LC‑MS/MS‑based targeted proteomics (PRM) with stable isotope‑labelled peptide standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous quantitation of both isoforms in a single run. The Substrate Specificity and Inhibitor Module evaluates the enzyme's activity against a custom panel of nucleotide analogues (e.g., IMP, XMP, GMP) and amino acid analogues to generate a specificity fingerprint that can distinguish between wild‑type and mutant ADSS, and to identify potential off‑target effects of inhibitor candidates. The Stability and Formulation Module subjects the enzyme to accelerated aging conditions (temperatures from 2°C to 40°C, pH 4‑9, and various ionic strengths) and monitors residual activity, aggregation (by SEC‑HPLC), and conformational integrity (by CD spectroscopy) over time. Using Arrhenius modelling and deactivation kinetics, we predict shelf‑life and identify critical degradation pathways (e.g., deamidation, oxidation, aggregation). All modules are validated with reference ADSS standards (recombinant or purified from natural sources) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Depth

Our platform consistently delivers performance that surpasses typical industry and academic standards. In activity assays, we achieve signal‑to‑noise ratios > 300:1 at the LOD, with linearity over four orders of magnitude and Z’‑factors consistently > 0.8, making our assays highly robust for high‑throughput screening. Our kinetic fitting software uses global non‑linear regression to provide precise estimates of K_m and V_max, with residual errors < 2%. For protein quantitation by PRM, our chromatographic gradient resolves isoform‑specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 3%. In inhibitor studies, we perform full dose‑response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish‑Bowden analyses to determine the mechanism of inhibition (competitive, uncompetitive, or mixed). Additionally, we offer isothermal titration calorimetry (ITC) to measure the binding thermodynamics of inhibitors, providing ΔH, ΔS, and binding stoichiometry with precision within ±2%. For clients requiring detailed structural insight, we perform hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) to map ligand‑binding sites and conformational changes. This multi‑dimensional data set enables our clients to not only quantify ADSS activity but also to understand the molecular basis of substrate recognition, catalytic mechanism, and inhibition, facilitating the rational design of therapeutic strategies and diagnostic tools.

Distinctive Advantages of Our ADSS Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix‑specific sample preparation protocols for a wide variety of ADSS sources—including tissue homogenates, cell lysates, clinical biopsies, and purified recombinant proteins—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of ADSS isoforms and their characterised kinetic, inhibition, and stability data, enabling rapid method setup and confident benchmarking. Third, we offer a rapid screening service using a microplate‑based spectrophotometric assay that provides semi‑quantitative activity data within 1 hour of sample receipt—ideal for high‑throughput screening of compound libraries or patient cohorts. Fourth, our customised kinetic and inhibition studies can be tailored to simulate physiological conditions, including the presence of GTP‑binding proteins and relevant purine metabolites. Fifth, we provide integrated data interpretation that links enzyme activity, isoform abundance, and inhibition profiles to biological or clinical outcomes (e.g., disease severity, drug efficacy), enabling clients to make informed decisions on candidate selection and patient stratification. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by regulatory authorities. Our team of enzymologists, metabolic biologists, and clinical researchers provides consultative interpretation, helping clients to design follow‑up experiments, predict in vivo efficacy, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision‑making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, IC₅₀, isoform ratio, and inhibitor mechanism) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, kinetic fits, and SPR sensorgrams; (iii) a statistical comparison of samples against reference standards or historical data, with p‑values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a low IC₅₀ value indicates a potent and selective ADSS inhibitor, or how a shift in the ADSS1/ADSS2 ratio may reflect metabolic reprogramming in muscle or cancer tissues. For clients with multiple compounds or patient cohorts, we provide multivariate analysis (PCA, PLS‑DA) to identify the most influential parameters and to guide selection. We also offer predictive models that estimate therapeutic efficacy or disease progression based on in vitro ADSS activity data, using our internally developed machine learning tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re‑analysis capability.

Broad Applications Across Cancer Research, Metabolic Diagnostics, and Drug Discovery

The versatility of our ADSS detection service spans a wide range of sectors. In cancer and metabolic research, we quantify ADSS activity and isoform expression to understand the role of purine synthesis in tumour proliferation and to evaluate the effects of anti‑metabolite therapies. In clinical diagnostics, we measure ADSS activity in patient samples (fibroblasts, lymphocytes, muscle biopsies) to support the diagnosis of ADSS deficiency and to monitor metabolic interventions. In drug discovery and pharmacology, our inhibition and kinetic assays are critical for identifying and optimising selective ADSS inhibitors for anti‑cancer, anti‑parasitic, and immunosuppressive applications. In quality control of biological reagents, we verify the activity and purity of recombinant ADSS standards. In academic research, our comprehensive profiling supports publication‑quality studies on enzyme regulation, structure‑function relationships, and purine metabolism. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. Our ability to tailor the analytical package to the specific isoform, sample type, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing ADSS analytics through continuous technological improvement. Our current R&D includes the development of microfluidic‑based single‑cell activity assays for ultra‑sensitive detection, and the application of machine learning algorithms to predict inhibitor potency from chemical structure. We actively participate in inter‑laboratory proficiency testing for enzyme activity and protein analysis, and we contribute to the development of reference standards for purine metabolism enzymes. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 1 business day for rapid screening to 12 business days for comprehensive kinetic, proteomic, and inhibition profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance research, drug development, and clinical care. We invite you to partner with us to unlock the full potential of your adenylosuccinate synthetase research.

In summary, our adenylosuccinate synthetase detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates activity quantification, isoform discrimination, inhibitor screening, and stability assessment. By combining advanced instrumentation with deep expertise in purine metabolism and enzymology, we empower our clients to accelerate drug discovery, improve diagnostic accuracy, and understand the molecular basis of metabolic disease. We look forward to supporting your ADSS analysis needs with our state‑of‑the‑art analytical platform.